A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Lopez JS, Haefliger S, Plummer R, Clement PM, Jeffry Evans TR, Läubli H, Roth P, Kristeleit R, Brazil L, Tabatabai G, Wick A, Wunderlich B, Beebe K, Eisner JR, Lane H, Engelhardt M, Kaindl T, Hau P, Hundsberger T, Steinbach J.
Lopez JS, et al. Among authors: laubli h.
Cell Rep Med. 2025 Jun 17;6(6):102165. doi: 10.1016/j.xcrm.2025.102165.
Cell Rep Med. 2025.
PMID: 40532659
Free PMC article.
Clinical Trial.